Overview
Not every program can be a priority. We help you evaluate your entire portfolio to identify the highest-value opportunities and the candidates that should be deprioritized. We look at regulatory feasibility, market potential, and development cost to optimize your R&D strategy.
Key Features
Portfolio prioritization ranking
Resource allocation modeling
Indication expansion strategy
Lifecycle extension opportunities
Our Process
1
Audit
Reviewing the status of all programs.
2
Rank
Scoring assets based on value and risk.
3
Optimize
Recommending a balanced portfolio mix.
Project Complete & Deliverables Provided
Frequently Asked Questions
We use a standardized scoring framework that accounts for therapeutic area-specific success rates. Oncology drugs have different baseline PTRS than cardiovascular drugs. We also assess competitive landscape, unmet medical need, and regulatory pathway clarity. This allows apples-to-apples comparison even when programs are at different stages and in different indications.
Why Choose Us
- Higher ROI on R&D spend
- Strategic focus
- Balanced risk profile
- Objective decision making
Get More Details
Request a personalized consultation and detailed information about this service.
Personalized consultation
Detailed service information
Custom timeline & proposal
We'll respond within 24 hours
Ready to get started?
Contact our team to discuss your specific needs for Portfolio Assessment.
Schedule ConsultationWhat Our Clients Say
"Our R&D budget was stretched across 8 programs. Adelphi's portfolio assessment revealed 2 programs with blocking issues and 3 with underexploited lifecycle opportunities. Reallocating resources let us advance our best assets faster while pursuing additional indications we hadn't considered."
Dr. Susan Mitchell
Chief Scientific Officer
Mid-Size Pharma
Related Services
Explore other ways we can support your regulatory needs